Clinical Trial Update: A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers [Phase 1, Phase 2]

View source ↗

Summary

This release reports the completion of a Phase 1/2 study of a HPV16-targeted immunotherapy in patients with HPV16+ recurrent/metastatic head and neck squamous c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• HPV16-targeted immunotherapy (Hookipa Biotech)

Snippet

Sponsor: Hookipa Biotech GmbH | Conditions: HPV-Related Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED